Company: SISI
Filing Date: 2025-02-18
Form Type: S-1
Source: 0001493152-25-007187
Chunk: 83

Company: SHINECO, INC.
Filing Date: 2025-02-18
Form: S-1
Chunk 83
---
 the Registrant’s directors and officers to the fullest extent permitted under the DGCL.

While the Registrant has not entered into indemnification agreements with any of its directors and officers, such individuals are the beneficiaries of the indemnification protections provided for in the Registrant’s amended and restated certificate of incorporate and amended and restated bylaws.

The Registrant does not maintain a directors’ and officers’ insurance policy pursuant to which the Registrant’s directors and officers are insured against liability for actions taken in their capacities as directors and officers.

Item 15. Recent Sales of Unregistered Securities.

Set forth below is information regarding securities issued by us within the past three years that were not registered under the Securities Act. All share and per share numbers below have been adjusted to reflect the (i) one-for-twenty (1-for-20) 1-for-10 reverse stock split of the shares that became effective on February 16, 2024 and (ii) one-for-24 reverse stock split of the shares that became effective on November 12, 2024.

On June 13, 2022, the Company entered into a certain stock purchase agreement with certain non-U.S. investors, pursuant to which the Company agreed to sell, and the investors agreed to purchase, severally and not jointly, an aggregate of 9,810.42 shares of common stock of the Company at a price of $508.80 per share in exchange for gross proceeds of $4,991,540.

On August 11, 2022, the Company entered into a securities purchase agreement (the “August 2022 Purchase Agreement”) with certain non-U.S. investors (the “August 2022 Investors”). Under the August 2022 Purchase Agreement, the Company agreed to sell to the Investors up to 8,007 shares of common stock at a per share purchase price of US$219.60 (subject to the terms and conditions of the August 2022 Purchase Agreement) for gross proceeds of up to US$1,758,340. In reliance on the August 2022 Investors’ representations to the Company, the shares issued in this offering were not subject to the registration requirements of the Securities Act, pursuant to Regulation S promulgated thereunder. As of March 31, 2024, the proceeds were fully collected, and all of the shares issuable under that transaction were issued.

On October 21, 2022, Shineco Life entered into a stock purchase agreement with Beijing Kanghuayuan Medicine